DiaMedica Therapeutics Inc. Marketable Securities (Current)
DiaMedica Therapeutics Inc. (DMAC) had Marketable Securities (Current) of $38.38 million as of 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Balance Sheet › Assets › Assets, Current › Cash, Cash Equivalents, and Short-Term Investments
us-gaap:MarketableSecuritiesCurrent · last filed 2026-08-10
- 2026-06-30: Marketable Securities, Current $38.38M.
- 2026-03-31: Marketable Securities, Current $46.46M.
- 2025-12-31: Marketable Securities, Current $44.24M.
- 2025-09-30: Marketable Securities, Current $51.99M.
| Period end | Marketable Securities, Current |
|---|---|
| 2026-06-30 | $38.38M 10-Q · filed 2026-08-10 |
| 2026-03-31 | $46.46M 10-Q · filed 2026-05-06 |
| 2025-12-31 | $44.24M 10-Q · filed 2026-08-10 |
| 2025-09-30 | $51.99M 10-Q · filed 2025-11-12 |
| 2025-06-30 | $25.93M 10-Q · filed 2025-08-12 |
| 2025-03-31 | $33.73M 10-Q · filed 2025-05-13 |
| 2024-12-31 | $41.12M 10-K · filed 2026-03-30 |
| 2024-09-30 | $46.06M 10-Q · filed 2024-11-13 |
| 2024-06-30 | $39.99M 10-Q · filed 2024-08-07 |
| 2024-03-31 | $44.42M 10-Q · filed 2024-05-08 |
| 2023-12-31 | $48.35M 10-K · filed 2025-03-17 |
| 2023-09-30 | $44.23M 10-Q · filed 2023-11-13 |
| 2023-06-30 | $34.53M 10-Q · filed 2023-08-14 |
| 2023-03-31 | $26.51M 10-Q · filed 2023-05-15 |
| 2022-12-31 | $28.77M 10-K · filed 2024-03-19 |
| 2022-09-30 | $33.31M 10-Q · filed 2022-11-09 |
| 2022-06-30 | $35.38M 10-Q · filed 2022-08-11 |
| 2022-03-31 | $38.02M 10-Q · filed 2022-05-04 |
| 2021-12-31 | $40.41M 10-K · filed 2023-03-28 |
| 2021-09-30 | $31.88M 10-Q · filed 2021-11-10 |
| 2021-06-30 | $19.07M 10-Q · filed 2021-08-11 |
| 2021-03-31 | $20.07M 10-Q · filed 2021-05-05 |
| 2020-12-31 | $20.10M 10-K · filed 2022-03-14 |
| 2020-09-30 | $20.83M 10-Q · filed 2020-11-04 |
| 2020-06-30 | $6.84M 10-Q · filed 2020-08-11 |
| 2020-03-31 | $9.35M 10-Q · filed 2020-05-13 |
| 2019-12-31 | $4.00M 10-K · filed 2021-03-10 |
| 2019-09-30 | $5.00M 10-Q · filed 2019-11-13 |
| 2019-06-30 | $7.99M 10-Q · filed 2019-08-13 |
| 2019-03-31 | $10.96M 10-Q · filed 2019-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |